1. Arcutis Biotherapeutics Inc. (NASDAQ:ARQT)
Arcutis Biotherapeutics takes the top spot in this May 2026 biotech list because the growth numbers are hard to ignore. Based on the provided data, the stock was priced at $21.17, with a 12-week price change of -18.14%, a forward P/E of 141.13, projected one-year EPS growth of 215.38%, and projected sales growth of 32.53%. That setup is exactly why Arcutis is interesting and risky at the same time. The valuation looks stretched, and the stock has pulled back recently, but the projected earnings growth and product revenue momentum make it one of the most exciting commercial-stage biotech names on the list.
Arcutis is focused on immuno-dermatology, which may sound less dramatic than oncology or rare disease biotech, but the commercial opportunity is very real. Skin diseases such as psoriasis, seborrheic dermatitis, and atopic dermatitis affect large patient populations and can create recurring treatment demand. The company’s key product family is ZORYVE, a roflumilast-based treatment platform offered in different formulations and strengths. For investors, the main question is whether ZORYVE can keep gaining share in branded topical treatments while Arcutis expands into more patient groups and prescriber channels.
The company’s first-quarter 2026 results showed strong year-over-year growth. Arcutis reported ZORYVE net product revenue of $105.4 million, up 65% compared with the first quarter of 2025, although it was down 17% from the fourth quarter of 2025 due mainly to typical first-quarter deductible resets and insurance changes. That seasonal decline matters, but the bigger year-over-year trend remains strong.
The revenue breakdown also gives investors more color. In the first quarter, ZORYVE cream 0.3% generated $32.7 million, ZORYVE topical foam 0.3% generated $49.6 million, ZORYVE cream 0.15% generated $21.7 million, and ZORYVE cream 0.05% generated $1.4 million. The company said the year-over-year growth was driven by strong unit demand and improvements in gross-to-net sales deductions.
Management said demand remained strong despite normal first-quarter seasonality. The company also said ZORYVE continues to grow its share of branded non-steroidal topical treatments. That detail matters because steroid-free dermatology options can be attractive to patients and physicians looking for alternatives in chronic inflammatory skin conditions. Investor’s Business Daily also reported earlier this year that Arcutis had received its sixth FDA approval for ZORYVE cream in dermatitis patients as young as two years old, which strengthened its profile in pediatric dermatology.
Arcutis is also working to expand the ZORYVE opportunity further. The company submitted a supplemental New Drug Application to the FDA for ZORYVE cream 0.05% to expand use in atopic dermatitis patients ages 3 to 24 months. It also completed enrollment in the ZORYVE foam 0.3% maximum usage systemic exposure trial in children ages 2 to 11 years with plaque psoriasis of the scalp and body. These pediatric expansion efforts could become important if approvals widen the addressable market.
The company has also moved into the next phase of commercial execution. Arcutis completed its dermatology sales force expansion at the beginning of May and started building a primary care and pediatrics-focused organization. This is a key operating detail because many biotech companies can win approval but struggle with commercialization. Arcutis is now trying to deepen prescriber adoption and improve reach, especially as it expands into broader dermatology and pediatric channels.
Another important point: Arcutis maintained positive operating cash flow for the quarter. For a fast-growing biotech company, that is a meaningful signal. Investors are watching not only revenue growth but also whether the company can support its commercial push without constantly relying on fresh capital.
READ ALSO: Top 10 Biotech Stocks That Could Explode in 2026 and Top 10 Small-Cap FDA Catalyst Biotech Stocks.
Disclosure: No relevant interests to disclose. This article was originally published on BioTech HealthX.
